Profound Medical shows strong revenue growth (+50.7%) but faces severe cash burn deterioration with operating cash flow worsening 63% to -$38.2M despite improving gross margins.
While the 50%+ revenue growth and improved gross margins (61.9% increase) suggest the commercial-stage medical device company is gaining market traction, the dramatic deterioration in cash burn raises immediate liquidity concerns. The company has shifted its business model description to emphasize "AI-powered" capabilities and simplified its revenue model, indicating potential strategic repositioning to capitalize on AI market trends.
The company demonstrates strong top-line momentum with revenue growing 50.7% to $16.1M and gross profit surging 61.9% to $11.4M, indicating improved operational efficiency and pricing power. However, this growth came at a steep cost as operating expenses expanded significantly (SG&A +38.5%, R&D +21.4%), driving net losses 53% deeper to -$42.6M and operating cash flow deteriorating 63% to -$38.2M. The balance sheet remains relatively stable with assets growing 10.3% and inventory building 42% to support growth, but the severe cash burn acceleration despite strong revenue growth signals potential working capital management issues and raises questions about the sustainability of current spending levels.
Operating cash flow fell 62.9% — earnings quality concerns; investigate working capital changes and non-cash items.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Net income declined 53% — review whether driven by operations, interest costs, or non-recurring items.
Strong top-line growth of 50.7% — accelerating demand or successful expansion into new markets.
Inventory surged 42% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.
SG&A up 38.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
R&D investment increased 21.4% — signals commitment to future product development, though near-term margin impact.
Liabilities increased 12.5% — monitor debt-to-equity ratio and interest coverage.
Asset base grew 10.3% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →